Tehran University of Medical Sciences
Tehran, 0098, Iran
NCT Number: NCT03260803
Osteoporosis fractures impose a significant economic burden on the health system. There is evidence that osteoporosis has a high prevalence in Iran (4.8% for men and 7.7% for women), and the frequency of osteopenia is 36.8% for men and 39.3% for women in Iran Accordingly, the prevention of osteopenia progression towards osteoporosis has been considered as an important issue in medicine. Bone is a dynamic tissue that is constantly being remodeled thus the equilibrium between bone formation and resorption done by simultaneously regulating osteoclasts and osteoblasts is important. Imbalance between bone deposition and resorption contributes to reducing bone mineral density and hence increasing the risk of osteoporosis
Recently, new therapies have been focused on use of medicinal herbs, especially phytochemicals. Among phytochemicals, phytonutrients, and especially polyphenols, can act both on osteoblast and on osteoclast.
Pine bark extract (oligopin) is a rich source of polyphenols that exerts strong antioxidant and anti-inflammatory activities. It has also beneficial effects on bone turnover based on in vitro studies and animal models. Investigators aimed to investigate the effects of oligopin on bone turnover markers and plasma and peripheral mononuclear cells oxidative stress in postmenopausal women with osteopenia in a double-blind randomized clinical trial. Participants are forty four women with osteopenia divided into two groups randomly (22, having oligopin, 150 mg, once daily, for 12 weeks). The 2nd group (22 women with osteopenia) receives the same amount of the placebo. At the first and the end of the study, blood sample are taken to measure in order to peripheral blood mononuclear cells isolation and plasma separation. The levels of bone alkaline phosphatase and carboxy terminal collagen type I in plasma oxidative stress markers such as total anti-oxidant capacity, malondialdehyde, and protein carbonyl were evaluated. Furthermore, oxidative stress will be evaluated in peripheral blood mononuclear cells by measurement of expression and activity of magnesium superoxide dismutase,catalase and Nuclear factor (erythroid-derived 2)-like 2.
Looking for future studies?
Notify Me50 year–65 year
Female
Interventional
Phase 3
Tehran, 0098, Iran
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fracture report during the study period; Unwillingness of participants to continue the project; The occurrence of any visible side effects of supplemental effects
-
Oligopin ,150 mg ,once daily, 12 week
Placebo,150 mg ,once daily, 12 week
Time frame: up to third month after intervention
Osteocalcin levels in plasma
Time frame: up to third month after intervention
Carboxyl terminal collagen type I in plasma
Time frame: up to third month after intervention
Osteocalcin/Carboxyl terminal collagen type I ratio
Time frame: Baseline and third month after intervention
MnSOD activity in peripheral blood mononuclear cells
Time frame: Baseline and third month after intervention
Catalase activity in peripheral blood mono nuclear cells
Time frame: Baseline and third month after intervention
MnSOD mRNA expression peripheral blood mononuclear cells
Time frame: Baseline and third month after intervention
Catalase mRNA expression peripheral blood mononuclear cells
Time frame: Baseline and third month after intervention
NrF2 mRNA expression peripheral blood mononuclear cells
Time frame: Baseline and third month after intervention
Malondialdehide levels in plasma
Time frame: Baseline and third month after intervention
total antioxidant capacity in plasma
Time frame: Baseline and third month after intervention
protein carbonyl content in plasma
Time frame: Baseline and third month after intervention
Total thiol level in plasma
Time frame: Baseline and third month after intervention
Catalase activity in plasma
Time frame: Baseline and third month after intervention
MnSOD activity in plasma
Tehran University of Medical Sciences
Other
Valuating the Effects of Oligopin Supplementation on the Turnover of Bone Formation and Antioxidant Changes in Postmenopausal Osteopenic Women: A Randomized Double-blind Clinical Trial With Placebo-concurrent Controls
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05541432
Behavior, Bone Diseases
Waterloo, Ontario, Canada
View Trial DetailsNCT06988033
Bone Diseases, Bone Diseases, Metabolic
Istanbul, Uskudar, Turkey (Türkiye)
View Trial DetailsNCT06813092
Behavior, Bone Diseases
Erlangen, Germany
View Trial DetailsNCT03483584
Avitaminosis, Bone Diseases
Shatin, Hong Kong
View Trial Details